权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

JHU-NUS Center for Research on CAMs(Planning Grant)

JHU-NUS CAM 研究中心（规划资助）

基本信息

批准号：
6802395
负责人：
PAUL S LIETMAN
金额：
$ 13.58万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2003
资助国家：
美国
起止时间：
2003-09-15 至 2006-03-31
项目状态：
已结题

项目摘要

DESCRIPTION (provided by applicant): This proposal is a response to an RFA (AT-03-002) from the National Center for Complementary and Alternative Medicine (NCCAM) entitled "PLANNING GRANT FOR INTERNATIONAL CENTERS FOR RESEARCH ON COMPLEMENTARY AND ALTERNATIVE MEDICINE (PICRC)". The unique position of Johns Hopkins in Singapore and the attributes of Singapore itself make Singapore an excellent site for an NIH NCCAM regional International Center for Research on Complementary and Alternative Medicine (ICRC). The proposal is from The Johns Hopkins University School of Medicine in Baltimore and the National University of Singapore and will include collaboration with units in China as well. The Principal Investigator, Paul S. Lietman is a physician-scientist with considerable experience in the organization and leadership of research entities that are focused on clinical research, clinical pharmacology, and the building of an international research unit in Singapore. He and the Singapore Co-Investigator, Eu Leong YONG, also a physician-scientist, have worked closely to assemble a team in Singapore (with JHU collaborators) that could significantly enhance the infrastructure of an embryonic CAM research capacity in Singapore and Southeast Asia. The goal of this proposal will be on the creation of a full-fledged grant application for an International Center for CAM Research (ICRC) in Singapore that includes 3 projects and a core facility. The proposal focuses on several of the most highly significant areas of CAM research, namely: 1. The standardization of TCM products to be studied by plant genomic and biochemical means, the reliable sourcing of herbs and edible plants, and the formulation and manufacturing of products following GMP 2. The development and validation of biomarkers that will facilitate the rigorous study of potentially bioactive herbal and food substances in humans 3. The elucidation of the cancer chemopreventative properties of edible tropical plants 4. The careful and rigorous conduct of clinical research that is essential to prove or disprove the biologic effects of potential therapeutic agents in humans and the clinical studies of interactions of TCMs with commonly prescribed chemotherapeutic agents.

描述（由申请人提供）：本提案是对国家补充和替代医学中心（NCCAM）题为“国际补充和替代医学研究中心（PICRC）计划拨款"的RFA（AT-03-002）的回应。约翰霍普金斯在新加坡的独特位置和新加坡本身的属性使新加坡成为NIH NCCAM区域补充和替代医学国际研究中心（红十字国际委员会）的绝佳地点。该提案来自巴尔的摩的约翰霍普金斯大学医学院和新加坡国立大学，并将包括与中国单位的合作。首席研究员保罗·S。Lietman是一位医生兼科学家，在组织和领导研究实体方面拥有丰富的经验，这些研究实体专注于临床研究，临床药理学以及在新加坡建立国际研究单位。他和新加坡的合作研究员Eu Leong YONG（也是一名医生和科学家）密切合作，在新加坡组建了一个团队（与JHU合作者），可以显著增强新加坡和东南亚的胚胎CAM研究能力的基础设施。该提案的目标是为新加坡的国际CAM研究中心（ICRC）创建一个完整的赠款申请，其中包括3个项目和一个核心设施。该提案侧重于CAM研究的几个最重要的领域，即： 1.通过植物基因组学和生物化学手段研究中药产品的标准化，可靠的草药和食用植物来源，以及按照GMP进行产品的配制和生产 2.生物标志物的开发和验证，将促进对人类潜在生物活性草药和食品物质的严格研究 3.可食用热带植物的癌症化学预防特性的阐明 4.仔细和严格地进行临床研究，这对于证明或反驳潜在治疗药物在人体中的生物学作用以及中药与常用化疗药物相互作用的临床研究至关重要。